Sanford C. Bernstein Upgrades Coloplast A/S (OTCMKTS:CLPBY) to “Hold”

Coloplast A/S (OTCMKTS:CLPBY) was upgraded by equities research analysts at Sanford C. Bernstein to a “hold” rating in a research note issued to investors on Wednesday,Zacks.com reports.

Coloplast A/S Trading Up 1.4%

Shares of CLPBY opened at $8.60 on Wednesday. Coloplast A/S has a 1-year low of $8.34 and a 1-year high of $11.73. The company has a current ratio of 1.61, a quick ratio of 1.00 and a debt-to-equity ratio of 1.20. The firm’s 50-day moving average price is $8.74 and its 200-day moving average price is $9.13. The firm has a market capitalization of $19.38 billion, a price-to-earnings ratio of 35.83, a PEG ratio of 0.81 and a beta of 0.26.

Coloplast A/S (OTCMKTS:CLPBY) last issued its quarterly earnings data on Tuesday, November 4th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.02). Coloplast A/S had a return on equity of 24.99% and a net margin of 13.01%.The company had revenue of $1.07 billion during the quarter, compared to analysts’ expectations of $1.10 billion. Sell-side analysts anticipate that Coloplast A/S will post 0.31 EPS for the current year.

Coloplast A/S Company Profile

Coloplast A/S is a global developer and manufacturer of medical devices and services focused on intimate healthcare. The company specializes in solutions designed to assist individuals with chronic medical conditions, aiming to improve quality of life through innovative products. Coloplast’s offerings span ostomy care, continence care, wound and skin care, and interventional urology, targeting patients who require long-term support and specialized treatments.

In its ostomy business, Coloplast provides pouches, skin barriers and accessories for patients who have had surgical procedures to divert bodily waste.